Base de dados : MEDLINE
Pesquisa : D02.033.100.291.630 [Categoria DeCS]
Referências encontradas : 277 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 277 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464879
[Au] Autor:Kainuma K; Kobayashi T; D'Alessandro-Gabazza CN; Toda M; Yasuma T; Nishihama K; Fujimoto H; Kuwabara Y; Hosoki K; Nagao M; Fujisawa T; Gabazza EC
[Ad] Endereço:Allergy Center, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan.
[Ti] Título:ß adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells.
[So] Source:Respir Res;18(1):79, 2017 May 02.
[Is] ISSN:1465-993X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial-mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full ß adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils. METHODS: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line. RESULTS: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific ß -adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol. CONCLUSIONS: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.
[Mh] Termos MeSH primário: Eosinófilos/fisiologia
Células Epiteliais/citologia
Células Epiteliais/fisiologia
Transição Epitelial-Mesenquimal/fisiologia
Procaterol/administração & dosagem
Mucosa Respiratória/citologia
Mucosa Respiratória/fisiologia
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Brônquios/citologia
Brônquios/diagnóstico por imagem
Brônquios/fisiologia
Linhagem Celular
Relação Dose-Resposta a Droga
Eosinófilos/citologia
Eosinófilos/efeitos dos fármacos
Células Epiteliais/efeitos dos fármacos
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Seres Humanos
Mucosa Respiratória/efeitos dos fármacos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12931-017-0563-4


  2 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28238903
[Au] Autor:Ito S; Uchida A; Isobe Y; Hasegawa Y
[Ad] Endereço:Department of Respiratory Medicine, Nagoya University School of Medicine, Nagoya 466-8550, Japan. Electronic address: itori@med.nagoya-u.ac.jp.
[Ti] Título:Responsiveness to bronchodilator procaterol in COPD as assessed by forced oscillation technique.
[So] Source:Respir Physiol Neurobiol;240:41-47, 2017 Jun.
[Is] ISSN:1878-1519
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this retrospective study was to assess responses to a bronchodilator by forced oscillation technique (FOT) and to relate the results of respiratory impedance (Zrs) to spirometric parameters in patients with chronic obstructive pulmonary disease (COPD). Zrs was measured as a function of frequency from 4 to 36Hz before and after inhalation of procaterol, a short-acting ß -agonist (n=60). Respiratory resistance (Rrs) and reactance (Xrs) were significantly frequency-dependent, and inspiratory and expiratory phases were different both before and after procaterol inhalation. The Rrs at 4Hz and Xrs at 4-20Hz during a whole breath were significantly improved after procaterol inhalation. The response to procaterol inhalation varied among patients, and changes in Xrs at 4Hz significantly correlated with% change in forced expiratory volume in one second and changes in forced vital capacity. Taken together, Zrs, and specifically Xrs parameters, are sensitive to acute physiological responses to a bronchodilator in COPD.
[Mh] Termos MeSH primário: Broncodilatadores/uso terapêutico
Volume Expiratório Forçado/efeitos dos fármacos
Procaterol/farmacologia
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Resistência das Vias Respiratórias/efeitos dos fármacos
Análise de Variância
Broncodilatadores/farmacologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Oscilometria
Procaterol/uso terapêutico
Testes de Função Respiratória
Estudos Retrospectivos
Espirometria
Volume de Ventilação Pulmonar/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bronchodilator Agents); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170426
[Lr] Data última revisão:
170426
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE


  3 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27880056
[Au] Autor:Taniguchi H; Furuse H; Nakanishi Y; Tsuda T; Totsuka K; Masaki Y; Suzuki K; Ishizawa S; Miyazawa H
[Ad] Endereço:a The Department of Internal Medicine , Toyama Prefectural Central Hospital , 2-2-78 Nishinage, Toyama , Japan.
[Ti] Título:Bronchial biopsy and reactivity in patients with chest tightness relieved with bronchodilator.
[So] Source:J Asthma;54(5):479-487, 2017 Jun.
[Is] ISSN:1532-4303
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: It has been hypothesized that some patients with chest tightness of unknown origin can be successfully treated with a bronchodilator and that they should be diagnosed with chest pain variant asthma. We conducted a prospective study to characterize newly diagnosed patients with chest tightness relieved with bronchodilator use and without characteristic bronchial asthma attacks. METHODS: Eleven patients were registered following recurrent positive responses of chest tightness to inhalation of a ß -agonist. These patients underwent assessments of airway responsiveness to methacholine, bronchial biopsy and bronchial lavage under fiber-optic bronchoscopy before receiving treatment. RESULTS: For the patients with chest tightness relieved with bronchodilator use, the bronchial biopsy specimens exhibited significant increases in lymphocyte and macrophage infiltration (p < 0.05) and no significant increase in eosinophils (p = 0.2918) compared with the control subjects. The bronchial responsiveness to methacholine was increased in two of the patients with chest tightness, and it was not increased in seven; in addition, increased percentages of eosinophils were detected in bronchial lavage fluid (5% or more) from two patients, but no increase was detected in eight patients. CONCLUSIONS: We suspect that the chest tightness was induced by airway constriction in these patients, but further study is necessary to validate this hypothesis. We propose that the chest tightness relieved with bronchodilator use was attributed to airway constriction resulting from inflammation with lymphocytes and macrophages and/or that the chest tightness was directly attributed to airway inflammation. This clinical trial is registered at www.umin.ac.jp (UMIN13994 and UMIN 16741).
[Mh] Termos MeSH primário: Broncodilatadores/farmacologia
Broncodilatadores/uso terapêutico
Dor no Peito/tratamento farmacológico
Dor no Peito/imunologia
[Mh] Termos MeSH secundário: Administração por Inalação
Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico
Adulto
Idoso
Obstrução das Vias Respiratórias/tratamento farmacológico
Obstrução das Vias Respiratórias/imunologia
Asma/tratamento farmacológico
Asma/imunologia
Hiper-Reatividade Brônquica
Testes de Provocação Brônquica
Líquido da Lavagem Broncoalveolar/citologia
Broncoscopia
Doença Crônica
Eosinófilos/metabolismo
Feminino
Fluticasona/farmacologia
Fluticasona/uso terapêutico
Seres Humanos
Linfócitos/metabolismo
Macrófagos/metabolismo
Masculino
Meia-Idade
Procaterol/farmacologia
Procaterol/uso terapêutico
Estudos Prospectivos
Testes de Função Respiratória
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Bronchodilator Agents); CUT2W21N7U (Fluticasone); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161124
[St] Status:MEDLINE
[do] DOI:10.1080/02770903.2016.1236940


  4 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27737734
[Au] Autor:Hijiya K; Chen-Yoshikawa TF; Kondo T; Motoyama H; Ohsumi A; Nakajima D; Sakamoto J; Ohata K; Takahashi M; Tanaka S; Miyamoto E; Aoyama A; Date H
[Ad] Endereço:Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
[Ti] Título:Bronchodilator Inhalation During Ex Vivo Lung Perfusion Improves Posttransplant Graft Function After Warm Ischemia.
[So] Source:Ann Thorac Surg;103(2):447-453, 2017 Feb.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We hypothesized that an injured lung graft from donation after cardiac death donors could be reconditioned before transplantation using an ex vivo lung perfusion (EVLP) system and ventilation with high-dose short-acting ß -adrenergic receptor agonists. METHODS: Cardiac arrest was induced in a canine model by intravenous potassium chloride injection. Lungs were randomly assigned to two groups after 150 minutes of warm ischemia: inhalation of 1,400 µg of procaterol (BETA group, n = 5) or control group receiving solvent (CON group, n = 5) during EVLP. Left lungs were transplanted after 120 minutes of EVLP. Functional variables, tissue adenosine 5'-triphosphate levels, and tissue cyclic adenosine monophosphate levels were measured 240 minutes after transplantation. RESULTS: Physiologic pulmonary function was similar at the end of EVLP in both groups. However, significantly better graft oxygenation, dynamic pulmonary compliance, and reduced pulmonary vascular resistance were observed in the BETA group than in the CON group 240 minutes after transplantation. No severe adverse effects were observed after lung transplantation in the BETA group. Lung tissue adenosine 5'-triphosphate levels and cyclic adenosine monophosphate levels were significantly higher in the BETA group than in the CON group at the end of EVLP and at 240 minutes after transplantation. CONCLUSIONS: High-dose nebulized procaterol during EVLP ameliorated lung graft dysfunction at the early posttransplantation period without severe adverse effects. These data suggest that lung reconditioning with procaterol ventilation during EVLP improves lung graft function after transplantation.
[Mh] Termos MeSH primário: Transplante de Pulmão/métodos
Preservação de Órgãos/métodos
Procaterol/administração & dosagem
Traumatismo por Reperfusão/prevenção & controle
Isquemia Quente/métodos
[Mh] Termos MeSH secundário: Administração por Inalação
Animais
Biópsia por Agulha
Broncodilatadores/administração & dosagem
Modelos Animais de Doenças
Cães
Rejeição de Enxerto
Sobrevivência de Enxerto/efeitos dos fármacos
Parada Cardíaca
Imuno-Histoquímica
Pulmão/patologia
Transplante de Pulmão/efeitos adversos
Perfusão
Distribuição Aleatória
Medição de Risco
Doadores de Tecidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bronchodilator Agents); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161015
[St] Status:MEDLINE


  5 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27274220
[Au] Autor:Kitaguchi Y; Yasuo M; Hanaoka M
[Ad] Endereço:First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
[Ti] Título:Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation.
[So] Source:Int J Chron Obstruct Pulmon Dis;11:991-7, 2016.
[Is] ISSN:1178-2005
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study was conducted in order to investigate the differences in the respiratory physiology of patients with chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOS), and asthma with airflow limitation (asthma FL(+)). METHODS: The medical records for a series of all stable patients with persistent airflow limitation due to COPD, ACOS, or asthma were retrospectively reviewed and divided into the COPD group (n=118), the ACOS group (n=32), and the asthma FL(+) group (n=27). All the patients underwent chest high-resolution computed tomography (HRCT) and pulmonary function tests, including respiratory impedance. RESULTS: The low attenuation area score on chest HRCT was significantly higher in the COPD group than in the ACOS group (9.52±0.76 vs 5.09±1.16, P<0.01). The prevalence of bronchial wall thickening on chest HRCT was significantly higher in the asthma FL(+) group than in the COPD group (55.6% vs 25.0%, P<0.01). In pulmonary function, forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate were significantly higher in the asthma FL(+) group than in the ACOS group (76.28%±2.54% predicted vs 63.43%±3.22% predicted, P<0.05 and 74.40%±3.16% predicted vs 61.08%±3.54% predicted, P<0.05, respectively). Although residual volume was significantly lower in the asthma FL(+) group than in the COPD group (112.05%±4.34% predicted vs 137.38%±3.43% predicted, P<0.01) and the ACOS group (112.05%±4.34% predicted vs148.46%±6.25% predicted, P<0.01), there were no significant differences in functional residual capacity or total lung capacity. The increase in FEV1 in response to short-acting ß2-agonists was significantly greater in the ACOS group than in the COPD group (229±29 mL vs 72±10 mL, P<0.01) and the asthma FL(+) group (229±29 mL vs 153±21 mL, P<0.05). Regarding respiratory impedance, resistance at 5 Hz and resistance at 20 Hz, which are oscillatory parameters of respiratory resistance, were significantly higher in the asthma FL(+) group than in the COPD group at the whole-breath (4.29±0.30 cmH2O/L/s vs 3.41±0.14 cmH2O/L/s, P<0.01 and 3.50±0.24 cmH2O/L/s vs 2.68±0.10 cmH2O/L/s, P<0.01, respectively), expiratory, and inspiratory phases. CONCLUSION: Although persistent airflow limitation occurs in patients with COPD, ACOS, and asthma FL(+), they may have distinct characteristics of the respiratory physiology and different responsiveness to bronchodilators.
[Mh] Termos MeSH primário: Asma/fisiopatologia
Pulmão/fisiopatologia
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Enfisema Pulmonar/fisiopatologia
[Mh] Termos MeSH secundário: Administração por Inalação
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Idoso
Resistência das Vias Respiratórias
Asma/diagnóstico
Asma/tratamento farmacológico
Broncodilatadores/administração & dosagem
Feminino
Volume Expiratório Forçado
Seres Humanos
Pulmão/diagnóstico por imagem
Pulmão/efeitos dos fármacos
Masculino
Registros Médicos
Inaladores Dosimetrados
Pico do Fluxo Expiratório
Fenótipo
Procaterol/administração & dosagem
Doença Pulmonar Obstrutiva Crônica/diagnóstico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Enfisema Pulmonar/diagnóstico
Enfisema Pulmonar/tratamento farmacológico
Estudos Retrospectivos
Espirometria
Síndrome
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Bronchodilator Agents); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.2147/COPD.S105988


  6 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27012982
[Au] Autor:Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H
[Ad] Endereço:Laboratory of Pharmaceutical Engineering, Gifu Pharmaceutical University, 1-25-4 Daigaku-Nishi, Gifu 501-1196, Japan.
[Ti] Título:Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.
[So] Source:Int J Pharm;505(1-2):139-46, 2016 May 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Drug inhalation provides localized drug therapy for respiratory diseases. However, the therapeutic efficacy of inhaled drugs is limited by rapid clearance from the lungs. Small hydrophilic compounds have short half-lives to systemic absorption. We developed a liposomal formulation as a sustained-release strategy for pulmonary delivery of procaterol hydrochloride (PRO), a short-acting pulmonary ß2-agonist for asthma treatment. After PRO-loaded liposomes were prepared using a pH gradient (remote loading) method, 100-nm liposomes improved residence times of PRO in the lungs. PRO encapsulation efficiency and release profiles were examined by screening several liposomal formulations of lipid, cholesterol, and inner phase. Although PRO loading was not achieved using the conventional hydration method, PRO encapsulation efficiency was >60% using the pH gradient method. PRO release from liposomes was sustained for several hours depending on liposomal composition. The liposomal formulation effects on the PRO behavior in rat lungs were evaluated following pulmonary administration in vivo. Sustained PRO release was achieved using simplified egg phosphatidylcholine (EPC)/cholesterol (8/1) liposome in vitro, and greater PRO remnants were observed in rat lungs following pulmonary administration. Extended pharmacological PRO effects were observed for 120min in a histamine-induced bronchoconstriction guinea pig model. We indicated the simplified EPC/cholesterol liposome potential as a controlled-release PRO carrier for pulmonary administration.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Lipídeos/química
Pulmão/metabolismo
Procaterol/administração & dosagem
[Mh] Termos MeSH secundário: Administração por Inalação
Agonistas de Receptores Adrenérgicos beta 2/farmacocinética
Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Animais
Broncoconstrição/efeitos dos fármacos
Química Farmacêutica/métodos
Colesterol/química
Preparações de Ação Retardada
Modelos Animais de Doenças
Sistemas de Liberação de Medicamentos
Cobaias
Histamina/metabolismo
Concentração de Íons de Hidrogênio
Lipossomos
Masculino
Tamanho da Partícula
Procaterol/farmacocinética
Procaterol/farmacologia
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Delayed-Action Preparations); 0 (Lipids); 0 (Liposomes); 820484N8I3 (Histamine); 97C5T2UQ7J (Cholesterol); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160326
[St] Status:MEDLINE


  7 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26990656
[Au] Autor:Krogh N; Backer V; Rzeppa S; Hemmersbach P; Hostrup M
[Ad] Endereço:Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark.
[Ti] Título:Pharmacokinetics of nebulized and oral procaterol in asthmatic and non-asthmatic subjects in relation to doping analysis.
[So] Source:Drug Test Anal;8(10):1056-1064, 2016 Oct.
[Is] ISSN:1942-7611
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of the present study was to investigate pharmacokinetics of procaterol in asthmatics and non-asthmatics after nebulized and oral administration in relation to doping. Ten asthmatic and ten non-asthmatic subjects underwent two pharmacokinetic trials. At first trial, 4 µg procaterol was administered as nebulization. At second trial, 100 µg procaterol was administered orally. Serum and urine samples were collected before and after administration of procaterol. Samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Serum and urine concentrations of procaterol were markedly higher after oral administration compared to nebulized administration. After oral administration, serum procaterol concentration-time area under the curve (AUC) was higher (P ≤ 0.05) for asthmatics than non-asthmatics. Likewise, urine concentrations were higher (P ≤ 0.01) for asthmatics than non-asthmatics 4 (47 ± 12 vs. 28 ± 9 ng/mL) and 8 h (39 ± 9 vs. 15 ± 5 ng/mL) after oral administration. Detection of serum procaterol was difficult after nebulized administration with 38 samples (27%) below limit of quantification (LOQ) and only trends were observed. No differences were observed between asthmatics and non-asthmatics in the urine concentrations of procaterol after nebulized administration. In summary, our data showed that asthmatics had higher urine concentrations of procaterol than non-asthmatics after oral administration of 100 µg, whereas no difference was observed between the groups after nebulized administration. For doping control purposes, our observations indicate that it is possible to differentiate therapeutic nebulized administration of procaterol from prohibited use of oral procaterol. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/urina
Asma/tratamento farmacológico
Cromatografia Líquida/métodos
Procaterol/administração & dosagem
Procaterol/farmacocinética
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Administração por Inalação
Administração Oral
Agonistas de Receptores Adrenérgicos beta 2/química
Doping nos Esportes
Seres Humanos
Procaterol/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170321
[Lr] Data última revisão:
170321
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160319
[St] Status:MEDLINE
[do] DOI:10.1002/dta.1935


  8 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26890828
[Au] Autor:Chen D; Yang M; Zheng N; Xie N; Liu D; Xie C; Yao D
[Ad] Endereço:Institute of Microbial Technology, Jinan University, Guangzhou 510632, China; National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou 510632, China.
[Ti] Título:A novel aptasensor for electrochemical detection of ractopamine, clenbuterol, salbutamol, phenylethanolamine and procaterol.
[So] Source:Biosens Bioelectron;80:525-531, 2016 Jun 15.
[Is] ISSN:1873-4235
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:ß-agonists are phenylethanolamines with different substituent groups on the aromatic ring and the terminal amino group which have the effect of nutrition redistribution and can accumulate in body tissues causing acute or chronic poisoning when consumed. Therefore, it is very important to establish a fast screening method for the detection of several kinds of ß-agonists in food safety control. In this study, the aptamer-agonists (AP-Ago) has screened out by Isothermal Titration Calorimetric method. AP-Ago was a single-strand DNA with 22 base-pairs. The dissociation constant (Kd) to phenylethanolamine (PHL) was 3.34 × 10(-5)mol L(-1). The AP-Ago based electrode was constructed by self-assembling on gold electrode. A label-free electrochemical aptasensor was then developed with AP-Ago-based gold electrode, which was sensitive to phenylethanolamine(PHL), clenbuterol (CLB), ractopamine (RAC), salbutamol (SAL) and procaterol (PRO). The detection limits were 0.04 ng/mL (RAC), 0.35 pg/mL (CLB), 1.0 pg/mL (PHL), 0.53 pg/mL (SAL) and 1.73 pg/mL(PRO), respectively, The detection time was 15 min. The reproductivity of the mentioned aptasensor is good with RSD of 2.09%. Comparing with ELISA and HPLC on ß-agonists detection in actual sample, this aptasensor is advantage of fewer steps and fast screen-detection of these five ß-agonists or their mixtures. This study suggests that the aptasensor can be developed to a rapid screening means with multi-ß-agonists (may be one or more) in sample.
[Mh] Termos MeSH primário: Técnicas Biossensoriais
Técnicas Eletroquímicas
Análise de Alimentos
[Mh] Termos MeSH secundário: Albuterol/isolamento & purificação
Aptâmeros de Nucleotídeos
Clembuterol/isolamento & purificação
DNA de Cadeia Simples/química
Ouro/química
Seres Humanos
Limite de Detecção
Fenetilaminas/isolamento & purificação
Procaterol/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aptamers, Nucleotide); 0 (DNA, Single-Stranded); 0 (Phenethylamines); 57370OZ3P1 (ractopamine); 7440-57-5 (Gold); QF8SVZ843E (Albuterol); X7I3EMM5K0 (Procaterol); XTZ6AXU7KN (Clenbuterol)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:170924
[Lr] Data última revisão:
170924
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160219
[St] Status:MEDLINE


  9 / 277 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26694294
[Au] Autor:Kondo T; Chen F; Date H
[Ad] Endereço:Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
[Ti] Título:Reply.
[So] Source:Ann Thorac Surg;101(1):412, 2016 Jan.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Pulmão/irrigação sanguínea
Procaterol/administração & dosagem
Traumatismo por Reperfusão/prevenção & controle
[Mh] Termos MeSH secundário: Animais
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:151223
[Lr] Data última revisão:
151223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:151224
[St] Status:MEDLINE


  10 / 277 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26694293
[Au] Autor:Mohamed MS
[Ad] Endereço:Universität zu Köln, 118 Deutz-Kalker St, Köln, Germany 50679. Electronic address: mohammed.shehatta1@gmail.com.
[Ti] Título:Insulin Supplementation of the Lung Graft Cold Preservation Solution.
[So] Source:Ann Thorac Surg;101(1):411-2, 2016 Jan.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Pulmão/irrigação sanguínea
Procaterol/administração & dosagem
Traumatismo por Reperfusão/prevenção & controle
[Mh] Termos MeSH secundário: Animais
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); X7I3EMM5K0 (Procaterol)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:151223
[Lr] Data última revisão:
151223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:151224
[St] Status:MEDLINE



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde